Výsledky vyhledávání

Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features

Autor: Wenqian Li, Yan Wu, Xiaosu Zhou, Hongxing Liu, Yunchao Su, Min Zhang, Gailing Zhang, Jiujiang He, Hui Wang, Peihua Lu, Dan Song, Fanyong Lv, Ting He, Junfang Yang, Xian Zhang, Lisong Song, Yanze Shi, Jingjing Li, Xin-an Lu

Publikováno v: Blood Adv

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is effective in patients with advanced B-cell acute lymphoblastic leukemia (B-ALL). However, efficacy data is sparse in subgroups of patients with high-risk features such as BCR-ABL+, TP53 muta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c87de1ef7856167092f9643a3ecd4d8
https://doi.org/10.1182/bloodadvances.2020001466

Zobrazit plný text záznamu

5 years of clinical DC-CIK/NK cells immunotherapy for acute myeloid leukemia - a summary

Autor: Hongxing Liu, Tong Wang, Peihua Lu, Lisong Song, Ping Wu, Dan Song, Min Zhang, Yang Zhang, Hui Wang, Yunchao Su, Yanze Shi, Fanyong Lv, Junfang Yang, Xian Zhang, Jiujiang He, Gailing Zhang

Publikováno v: Immunotherapy. 12(1)

Aim: To assess the efficacy of dendritic cells-cytokine induced killer (DC-CIK) and natural killer (NK) cell-based immunotherapy in treating the low- and intermediate-risk acute myeloid leukemia. Patients & methods: DC-CIK or NK cells were infused on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45176706a129389954f726efae11aa84
https://pubmed.ncbi.nlm.nih.gov/31914839

Zobrazit plný text záznamu

A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia

Autor: Qinglong Wang, Xiao-Ling Guo, Fanyong Lv, Dandan Chen, Junfang Yang, Xian Zhang, Jianqiang Li, Peihua Lu, Lin Wang, Jinhai Ren, Xiaosu Zhou

Publikováno v: Blood. 132:277-277

Introduction: Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has recently demonstrated high success but also shown limitations regarding their toxicity and development of CD19negative variants. Here we reported results from a phase I s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a6e21976f92b5712d212a231ce3a242a
https://doi.org/10.1182/blood-2018-99-114415

Zobrazit plný text záznamu

Efficacy and Safety of CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphocytic Leukemia (B-cell ALL) in a Large Cohort Including Patients with Extramedullary Disease(EMD), High Leukemia Burden, BCR-ABL (+) Mutation,TP53 Mutation, and Post-Transplant Relapse

Autor: Fanyong Lv, Peihua Lu, Jian-Ping Zhang, Xiaosu Zhou, Xin-an Lu, Ting He, Junfang Yang, Xian Zhang, Min Xiong

Publikováno v: Blood. 132:280-280

Introduction: CD19 CAR-T therapy is effective for B-cell ALL. However, whether patients (pts) with EMD, High Leukemia Burden (HLB), TP53 mutation, BCR-ABL (+) mutation, or post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cf4ed1209625fbd2dd7d891b788ea84
https://doi.org/10.1182/blood-2018-99-115642

Zobrazit plný text záznamu

A Long-Term Retrospective Analysis of Arsenic-Containing Triple-Agents Treatment for Acute Promyelocytic Leukemia (APL) in a Cohort from a Single Hospital

Autor: Peihua Lu, Junfang Yang, Xian Zhang, Yunchao Su, Gailing Zhang, Fanyong Lv

Publikováno v: Blood. 132:4060-4060

Objective: The long-term efficacy (June 2001 - May 2018) of newly diagnosed APL patients (pts) treated with either As4S4 or As2O3 in combination of all-trans retinoid acid (ATRA), and anthracycline-based chemotherapy in Lu Dao-Pei Hospital is analyze

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f24bcb5f04a9da50250712344d25c200
https://doi.org/10.1182/blood-2018-99-117795

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání